Showing results (351-360 of 378) with videos related to

Sort By:
Pageof 38
Cancers|September 10, 2021
Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International AnalysisLaith Samhouri, Mohamed A M Meheissen, Ahmad K H Ibrahimi, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Acta Neurochirurgica|September 25, 2014
Predicting the "usefulness" of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European surveyWalter Stummer, Floriano Rodrigues, Philippe Schucht, et al.
Cancer Research|October 28, 2025
Integrated Single-Nucleus and Spatial Transcriptomics Elucidate Heterogeneity and Hypoxia-Driven Organization of Supratentorial EpendymomaErik Schüftan, I-Na Lu, Flavia W de Faria, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neuro-Oncology|March 20, 2024
Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticatorAlice Ryba, Zeynep Özdemir, Nitzan Nissimov, et al.
Acta Neuropathologica|March 23, 2021
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymomaChristian Thomas, Felix Thierfelder, Malte Träger, et al.
Neuro-Oncology Advances|October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastomaLazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Cancer Medicine|April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging AnalysisLazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.
Pageof 38